TRVIMEDIUM SIGNALOPPORTUNITY10-K

TRVI substantially strengthened its balance sheet through an apparent equity raise while refining its clinical narrative around Haduvio's dual mechanism of action as a kappa agonist/mu antagonist (KAMA) targeting chronic cough in IPF patients.

The balance sheet expansion — stockholders' equity growing roughly 84% to $183.2M and total assets rising ~74% to $193.4M — strongly suggests a successful capital raise, extending the company's runway as it advances Haduvio into planned clinical trials. The language changes reflect a more precise and technically detailed description of Haduvio's mechanism, which may indicate increased regulatory and clinical maturity of the program heading into pivotal-stage work. Investors should note that the updated risk language specifically calls out planned Phase 2 trial results, signaling the company is approaching a near-term binary clinical catalyst.

Comparing 2026-03-17 vs 2025-03-18View on EDGAR →
FINANCIAL ANALYSIS

The balance sheet meaningfully expanded, with current assets rising to $191.7M and stockholders' equity reaching $183.2M, most likely driven by an equity financing event rather than operating performance. Partially offsetting this, cash and equivalents declined to $18.9M from $34.1M (-44.5%), while operating cash outflow widened modestly to -$42.1M, reflecting continued pre-revenue R&D spending — though R&D expense itself declined approximately 15% to $33.5M, suggesting some moderation in cash burn. Net loss narrowed modestly to -$42.8M and interest expense fell meaningfully to $391K, together painting a picture of a clinical-stage company that has secured fresh capital but remains dependent on continued financing to fund its development pipeline.

FINANCIAL STATEMENT CHANGES
Stockholders Equity
Balance Sheet
+83.9%
$99.6M→$183.2M

Equity base grew 83.9% — retained earnings accumulation or equity issuance strengthening the balance sheet.

Current Assets
Balance Sheet
+75.1%
$109.4M→$191.7M

Current assets grew 75.1% — improving short-term liquidity or inventory/receivables build.

Total Assets
Balance Sheet
+74.4%
$110.9M→$193.4M

Asset base grew 74.4% — expansion through organic growth, acquisitions, or capital deployment.

Interest Expense
P&L
-66.4%
$1.2M→$391K

Interest expense declined — debt repayment or refinancing at lower rates improving earnings quality.

Capital Expenditure
Cash Flow
-65.7%
$35K→$12K

Capex reduced 65.7% — investment cycle winding down or capital discipline; may improve near-term free cash flow.

Cash & Equivalents
Balance Sheet
-44.5%
$34.1M→$18.9M

Cash declined 44.5% — significant cash burn or deployment; verify adequacy of remaining liquidity runway.

R&D Expense
P&L
-15%
$39.4M→$33.5M

R&D spending cut 15% — could signal cost discipline or concerning reduction in innovation investment.

Net Income
P&L
+10.8%
-$47.9M→-$42.8M

Net income grew 10.8% — bottom-line growth signals improving overall business health.

Operating Cash Flow
Cash Flow
-10%
-$38.3M→-$42.1M

Operating cash flow softened — monitor whether temporary working capital timing or structural deterioration.

LANGUAGE CHANGES
NEW — 2026-03-17
PRIOR — 2025-03-18
ADDED
For instance, Haduvio may fail to show the desired safety and efficacy results in our planned trials of Haduvio despite demonstrating positive results in earlier Phase 2 clinical trials.
Exhibits, Financial Statement Schedules 93 Item 16 Form 10-K Summary 95 PART I Item 1.
Haduvio acts on the cough reflex arc both centrally and peripherally as a k appa receptor a gonist and a m u receptor a ntagonist ( KAMA ), targeting opioid receptors that play a key role in controlling chronic cough.
Nalbuphine has been approved and marketed as an injectable for pain indications for decades in the United States, or the U.S., and Europe.
Parenteral nalbuphine is not scheduled as a controlled substance by the U.S.
We are developing Haduvio for the treatment of IPF-related chronic cough, which is a progressive fibrosing interstitial lung disease associated with high mortality rates.
After an IPF diagnosis, the median survival is 3 to 5 years, during which time patients suffer from chronic cough, dyspnea, and fatigue.
IPF-related chronic cough is a condition with high unmet need and no therapies approved by the U.S.
patients with IPF, and two-thirds of these patients have uncontrolled chronic cough.
The impact of chronic cough is significant, with patients coughing up to 1,500 times per day.
REMOVED
For instance, Haduvio may fail to show the desired safety and efficacy in clinical development despite demonstrating positive results in earlier clinical trials.
Exhibits, Financial Statement Schedules 92 Item 16 Form 10-K Summary 94 PART I Item 1.
Haduvio acts on the cough reflex arc both centrally and peripherally as a kappa agonist and a mu antagonist, or KAMA.
Kappa and mu are opioid receptors that play a key role in controlling cough hypersensitivity.
Nalbuphine has been approved and marketed as an injectable for pain indications for more than 30 years in the United States, or the U.S., and Europe.
Parenteral nalbuphine is not scheduled as a controlled substance in the U.S.
IPF is a rare, chronic, progressive lung disease, characterized by scarring and thickening of lung tissue leading to a loss of lung function and reduced life expectancy.
Most patients diagnosed with IPF suffer from a dry, non-productive chronic cough that interrupts their daily living and contributes to poor quality of life.
Chronic coughing can have a debilitating physical and psychosocial burden, exacerbate concomitant respiratory disease, cause loss of sleep and reduce mobility.
Cough may be an independent predictor of disease progression in IPF, and therefore we believe cough may contribute to the progression of the underlying disease.
MORE OPPORTUNITY SIGNALS
ABTHIGHAbbott announced a major strategic acquisition of Exact Sciences Corporation to ...
2026-02-20
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →